Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426605 · ClinicalTrials.gov registry record · Phase 1
A Study of LAM-003 in Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by OrphAI Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03426605 is a Phase 1 study that has completed, run by OrphAI Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT03426605, a Phase 1 study, has completed, sponsored by OrphAI Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia
Interventions
- DRUG Open Label LAM-003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2020-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03426605
The ClinicalTrials.gov registry entry for NCT03426605 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OrphAI Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Open Label LAM-003 is the first listed.
NCT03426605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03426605 about?
NCT03426605 is a clinical study titled "A Study of LAM-003 in Patients With Acute Myeloid Leukemia". A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia
What is the current status of trial NCT03426605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2018-01-16. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT03426605?
The interventions under investigation include: Open Label LAM-003 (DRUG).
Who is sponsoring clinical trial NCT03426605?
This trial is sponsored by OrphAI Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.